Lung Cancer
Volume 55, Issue 1 , Pages 61-66, January 2007

Evaluation of extratumoral lymphatic permeation in non-small cell lung cancer as a means of predicting outcome

  • Takamoto Saijo

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
    • Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • Corresponding Author InformationCorresponding author at: Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Tel.: +81 471 33 1111; fax: +81 471 31 4724.
  • ,
  • Genichiro Ishii

      Affiliations

    • Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
  • ,
  • Atsushi Ochiai

      Affiliations

    • Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
  • ,
  • Takahiro Hasebe

      Affiliations

    • Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
  • ,
  • Junji Yoshida

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
  • ,
  • Mitsuyo Nishimura

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
  • ,
  • Kanji Nagai

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan

Received 10 March 2006; received in revised form 2 August 2006; accepted 25 September 2006.

Summary 

Background

Lymphatic permeation (ly) has been described as a potential prognostic factor for non-small cell lung cancer (NSCLC).

Methods

The purpose of this study was to analyze whether evaluation of the presence or absence of ly and its location (ly 0: absent, N=464; ly 1: intratumoral, N=42; ly 2: extratumoral, N=52) provides an appropriate means of predicting the outcome of NSCLC. We investigated the clinical implications of ly in 558 consecutive patients with surgically resected NSCLC.

Results

Evaluation according to ly status showed that the recurrence-free survival (RFS) time of the ly 2 patients was significantly shorter than that of the ly 0 patients (P<0.0001), the ly 1 patients (P=0.0028). A significant difference in RFS time was also observed between the ly 0 patients and the ly 1 patients (P=0.0025). RFS time of the ly 0 patients was significantly longer than that of the ly 1 plus ly 2 patients (P<0.0001). We also evaluated the patients with pathological stage I disease (N=378) separately. The RFS time of the ly 2 patients (N=9) was significantly shorter than that of the ly 0 plus ly 1 patients (P<0.0001). In the nine ly 2 patients, six developed a distant metastasis within 1 year. A multivariate analysis revealed that ly status (ly 0 plus ly 1 versus ly 2) was an independent prognostic factor (P=0.0116), demonstrating the significant prognostic value of extratumoral lymphatic permeation in NSCLC.

Conclusions

These results indicate that ly status is a good prognostic marker of poorer outcome in patients with resected NSCLC.

Keywords: NSCLC, Lymphatic permeation, Extratumoral, Intratumoral, Prognostic factor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(06)00526-5

doi:10.1016/j.lungcan.2006.09.027

Lung Cancer
Volume 55, Issue 1 , Pages 61-66, January 2007